CA3176042A1 - Processes for the preparation of a kinase inhibitor - Google Patents
Processes for the preparation of a kinase inhibitorInfo
- Publication number
- CA3176042A1 CA3176042A1 CA3176042A CA3176042A CA3176042A1 CA 3176042 A1 CA3176042 A1 CA 3176042A1 CA 3176042 A CA3176042 A CA 3176042A CA 3176042 A CA3176042 A CA 3176042A CA 3176042 A1 CA3176042 A1 CA 3176042A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- solvent
- formula
- reaction mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017739P | 2020-04-30 | 2020-04-30 | |
| US63/017,739 | 2020-04-30 | ||
| PCT/US2021/030035 WO2021222673A1 (en) | 2020-04-30 | 2021-04-30 | Processes for the preparation of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3176042A1 true CA3176042A1 (en) | 2021-11-04 |
Family
ID=76076455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3176042A Pending CA3176042A1 (en) | 2020-04-30 | 2021-04-30 | Processes for the preparation of a kinase inhibitor |
Country Status (27)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154105A (zh) | 1994-06-08 | 1997-07-09 | H·隆德贝克有限公司 | 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物 |
| ZA954689B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
| SMP200900002B (it) | 2006-06-12 | 2010-01-19 | Novartis Ag | Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide |
| CN101466672B (zh) | 2006-06-12 | 2012-05-16 | 诺瓦提斯公司 | N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐 |
| CA2743416A1 (en) * | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
| TW201920110A (zh) * | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| WO2012009722A1 (en) * | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| PL2768796T3 (pl) | 2011-10-20 | 2020-05-18 | Exelixis, Inc. | Sposób wytwarzania pochodnych chinoliny |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| SG11202006945PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2021
- 2021-04-30 FI FIEP21727657.5T patent/FI4143169T3/fi active
- 2021-04-30 DK DK21727657.5T patent/DK4143169T3/da active
- 2021-04-30 LT LTEPPCT/US2021/030035T patent/LT4143169T/lt unknown
- 2021-04-30 MA MA59466A patent/MA59466B1/fr unknown
- 2021-04-30 TW TW110115786A patent/TWI887405B/zh active
- 2021-04-30 MX MX2022013528A patent/MX2022013528A/es unknown
- 2021-04-30 SI SI202130435T patent/SI4143169T1/sl unknown
- 2021-04-30 JP JP2022566135A patent/JP7728795B2/ja active Active
- 2021-04-30 US US17/922,208 patent/US12497367B2/en active Active
- 2021-04-30 CA CA3176042A patent/CA3176042A1/en active Pending
- 2021-04-30 KR KR1020227037607A patent/KR20230005190A/ko active Pending
- 2021-04-30 AU AU2021263474A patent/AU2021263474A1/en active Pending
- 2021-04-30 PT PT217276575T patent/PT4143169T/pt unknown
- 2021-04-30 PH PH1/2022/552821A patent/PH12022552821A1/en unknown
- 2021-04-30 CN CN202180031136.7A patent/CN115461328B/zh active Active
- 2021-04-30 CR CR20220551A patent/CR20220551A/es unknown
- 2021-04-30 WO PCT/US2021/030035 patent/WO2021222673A1/en not_active Ceased
- 2021-04-30 EP EP21727657.5A patent/EP4143169B1/en active Active
- 2021-04-30 RS RS20260593A patent/RS68116B1/sr unknown
- 2021-04-30 BR BR112022021712A patent/BR112022021712A2/pt unknown
- 2021-04-30 GE GEAP202516101A patent/GEP20267875B/en unknown
- 2021-04-30 HR HRP20260608TT patent/HRP20260608T1/hr unknown
- 2021-04-30 PE PE2022002513A patent/PE20230110A1/es unknown
- 2021-04-30 SM SM20260219T patent/SMT202600219T1/it unknown
- 2021-04-30 CN CN202511511945.4A patent/CN121591655A/zh active Pending
-
2022
- 2022-10-26 IL IL297684A patent/IL297684B2/en unknown
- 2022-10-26 CO CONC2022/0015205A patent/CO2022015205A2/es unknown
- 2022-10-28 CL CL2022003008A patent/CL2022003008A1/es unknown
-
2025
- 2025-06-20 JP JP2025104881A patent/JP2025128388A/ja active Pending
- 2025-10-21 IL IL324105A patent/IL324105A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3067941C (en) | Coumarin-like cyclic compound as mek inhibitor and use thereof | |
| IL324105A (en) | Processes for the preparation of a kinase inhibitor | |
| AU2018236290A1 (en) | MK2 inhibitors, synthesis thereof, and intermediates thereto | |
| WO2022165148A1 (en) | Mk2 inhibitors, the synthesis thereof, and intermediates thereto | |
| WO2020206588A1 (en) | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| CA2555825A1 (en) | Process for the preparation of substituted triazole compounds | |
| CN114727977A (zh) | 化合物和化合物s1p1调节剂的制备方法 | |
| JP7502997B2 (ja) | フェノキシジアミノピリミジン化合物の新規な合成方法 | |
| JP7068402B2 (ja) | チアゾール誘導体の製造方法 | |
| EP4249077A1 (en) | Novel acridinium salt and method for producing same | |
| EA052237B1 (ru) | Способы получения ингибитора киназы | |
| AU2017364332A1 (en) | Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof | |
| TWI908573B (zh) | 芳香醯肼類衍生物及其醫藥用途 | |
| CN111943853B (zh) | 一种培唑帕尼杂质的制备方法 | |
| CA3214107A1 (en) | New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds | |
| CN117430561A (zh) | 一种gpr139受体激动剂及其制备方法 | |
| JP2024537339A (ja) | ベンゾフラン誘導体の調製方法 | |
| BR122025013614A2 (pt) | Processo para preparar um inibidor de jak, seus intermediários e formas cristalinas | |
| JP2018070607A (ja) | アミノ基で置換されたオキサジアゾール誘導体の製造方法 | |
| HK40006951B (en) | Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof | |
| JP2004175737A (ja) | 医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250407 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250407 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250416 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250416 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250416 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250603 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250603 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250603 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250603 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250605 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260304 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260709 |